Table 2.
MAIC results for efficacy outcomes
| RESORCE Rego (ESS = 214) versus placebo (ESS = 82) | CELESTIAL Cabo (N = 241) versus placebo (N = 117)a | Rego versus cabo | |
|---|---|---|---|
| OS (months) | |||
| Overall HR (95% CI) | 0.59 (0.44, 0.79) | 0.74 (0.56, 0.97) | 0.80 (0.54, 1.20) |
| RMST difference (95% CI) at 37.3 months | 5.42 (2.91, 7.94) | 2.67 (−0.16, 5.50) | 2.76 (−1.03, 6.54) |
| RMST ratio (95% CI) at 37.3 months | 1.58 (1.25, 1.99) | 1.21 (0.98, 1.50) | 1.30 (0.95, 1.79) |
| RMST difference (95% CI)b | 6.01 (3.01, 9.01) | 2.67 (−0.16, 5.50) | 3.34 (−0.78, 7.46) |
| RMST ratio (95% CI)b | 1.61 (1.24, 2.10) | 1.21 (0.98, 1.50) | 1.33 (0.95, 1.87) |
| PFS (months) | |||
| Overall HR (95% CI) | 0.43 (0.32, 0.57) | 0.43 (0.33, 0.55) | 1.00 (0.68, 1.49) |
| RMST difference (95% CI) at 15.2 months | 2.51 (1.63, 3.39) | 3.10 (2.22, 3.97) | −0.59 (−1.83, 0.65) |
| RMST ratio (95% CI) at 15.2 months | 1.98 (1.51, 2.59) | 1.87 (1.54, 2.28) | 1.06 (0.76, 1.48) |
| RMST difference (95% CI)c | 2.51 (1.63, 3.39) | 3.38 (2.28, 4.47) | −0.87 (−2.27, 0.54) |
| RMST ratio (95% CI)c | 1.98 (1.51, 2.59) | 1.91 (1.51, 2.41) | 1.04 (0.72, 1.48) |
Cabo, cabozantinib; CI, confidence interval; ESS, effective sample size; HR, hazard ratio; MAIC, matching-adjusted indirect comparison; rego, regorafenib; RMST, restricted mean survival time.
a
Derived from recreated individual patient data from ref. [17].
b
Truncation time for RMST analyses was 50.6 months for RESORCE and 37.3 months for CELESTIAL, representing the minimum of the longest observed time between arms within each trial.
c
Truncation time for RMST analyses was 15.2 months for RESORCE and 22.2 months for CELESTIAL, representing the minimum of the longest observed time between arms within each trial.